Parkinson´s disease (PD) is a neurodegenerative disease, partially characterized by the loss of dopaminergic neurons in the substantia nigra and their projections to the striatum, causing a wide range of motor deficits. The most used treatment to date is the L-DOPA administration, however it has limited efficacy and diverse side effects, like diskynesias.It was recently demonstrated that P2X7R participates of neurodegenerative pathways, and their expression can be regulated by PGC-1± activation, a protein involved in the control of cell bioenergetics that blocks the loss of dopaminergic neurons in cellular models of PD. Therefore, its activation may be a novel therapeutic target for PD treatment.Another promising alternative for PD treatment is cell replacement, using neural stem cells. The present project aims to combine neural progenitor cell therapy together with P2X7R blockers and PGC-1± activators in animal models for PD. We also aim to evaluate whether the activation of PGC-1± can trigger P2X7R inhibition, by its own, and is able to induce neuroprotection.
News published in Agência FAPESP Newsletter about the scholarship: